S1 Ep30: Impact of the JAK Inhibitor Approval Delays

This episode takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. Mark Lebwohl, MD, discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class. 

Om Podcasten

From the latest updates in dermatology to exclusive interviews with leading industry experts and a glimpse at what goes on behind the scenes, the staff at Dermatology Times brings you a podcast that will explore the impact of new data and support you in implementing innovative technologies that advance your patient care and practice. Join us under the dermatoscope for The Cutaneous Connection.